Rising Pharmaceuticals Introduces Edetate Calcium Disodium Injection
Rising Pharma Holdings, Inc., known as Rising Pharmaceuticals, has announced the launch of Edetate Calcium Disodium injection, an important medical product for treating lead poisoning. This announcement comes at a time when securing access to crucial medical therapies in the U.S. can be particularly challenging.
What is Edetate Calcium Disodium Injection?
Edetate Calcium Disodium injection is mainly used in clinical environments to lower blood lead levels and treat lead poisoning. It is suitable for both children and adults suffering from lead toxicities, including serious conditions like lead encephalopathy, which can occur from prolonged lead exposure.
Purpose and Advantages
This injection provides healthcare professionals with another treatment option, particularly useful during periods when other products may be in short supply. David Picard, Executive Vice President for Institutional Markets at Rising, highlighted the company’s dedication to making sure essential medicines are readily available. This consistent supply is part of Rising’s broader effort to aid healthcare providers in effectively managing their patients' needs.
Product Details
Rising's Edetate Calcium Disodium is packaged in a 5 mL single-dose vial, each containing 200 mg of the active ingredient per mL, totaling 1000 mg in each vial. These vials are sold in boxes of five and are classified under the National Drug Code (NDC) 64980-588-51. This packaging format helps healthcare facilities maintain sufficient stock for patient administration.
Clinical Use
Once administered, Edetate Calcium Disodium effectively binds to lead in the body, aiding in its removal. Healthcare professionals are required to closely monitor patients since the medication can lead to toxic side effects if not managed correctly. The injection can be given intravenously or intramuscularly, with specific dosing determined by how severely the patient has been exposed to lead.
Key Warnings and Considerations
Healthcare providers need to remain vigilant about potential side effects, such as nephrotoxicity, especially in patients with existing kidney issues. Regular evaluations of kidney function and urine output are critical to prevent complications. Consistent monitoring of kidney health is essential throughout treatment, and dosages may need adjustment based on the patient's renal status.
About Rising Pharmaceuticals
Rising Pharmaceuticals is a significant player in the U.S. generic and specialty pharmaceutical markets. The company boasts over 182 commercialized generic medicines and more than 620 active stock-keeping units (SKUs), allowing it to cater to diverse healthcare needs. Rising works in partnership with strategic manufacturers worldwide, ensuring a reliable supply chain that supports the distribution of nearly 9 billion doses of medicines annually.
In Summary
The launch of Edetate Calcium Disodium injection by Rising Pharmaceuticals expands treatment options for individuals affected by lead poisoning. With a steadfast commitment to both quality and accessibility, Rising Pharmaceuticals aims to enhance the management of lead toxicity, significantly benefiting public health.
Frequently Asked Questions
What is Edetate Calcium Disodium used for?
Edetate Calcium Disodium is primarily used to lower blood lead levels in patients with lead poisoning.
Who can receive this injection?
It is suitable for both children and adults experiencing lead toxicity, including cases of lead encephalopathy.
How is the injection administered?
The medication can be given intravenously or intramuscularly, depending on the patient's needs and clinical context.
What precautions should be taken?
Physicians must closely monitor renal function and urine output during treatment to mitigate the risk of nephrotoxicity.
Where is Rising Pharmaceuticals located?
The company is based in New Brunswick, New Jersey, where it manages its wide range of generic medications.
